No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
67 |
4. Check minimum number of eventsNone |
67 |
5. Include endpointsNone |
67 |
6. Filter based on genotype QC (FinnGen only) |
54 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
- Parent code in ICD-10
- C45-C49
- Name in latin
- Sarcoma Kaposi
Similar endpoints
↥List of similar endpoints to
Kaposi sarcoma, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of mesothelium and soft tissue, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
- Neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 54 | 13 | 41 |
| Unadjusted period prevalence (%) | 0.02 | 0.00 | 0.02 |
| Median age at first event (years) | 73.32 | 67.62 | 75.13 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 62
- Matched controls
- 620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C46.0
ICD-10 Finland
Kaposi sarcoma of skin
+∞
48.4
40
*
9140/3-C44.7
ICD-O-3
Kaposi sarcoma of skin of lower limb and hip
+∞
24.6
22
*
C46.9
ICD-10 Finland
Kaposi sarcoma, unspecified
+∞
12.9
12
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
11.8
11
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
16.3
11.2
18
15
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
43.7
9.4
11
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
24.3
8.9
12
6
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
8.5
8
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
8.5
8
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
7.4
7
*
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
16.3
7.2
11
8
WZC00
NOMESCO Finland
Treatment plan or consultation
4.2
6.6
24
81
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
77.5
6.6
7
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
77.5
6.6
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
6.3
6
*
9140/3-C44.9
ICD-O-3
Kaposi sarcoma of skin, NOS
+∞
6.3
6
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
C46.3
ICD-10 Finland
Kaposi sarcoma of lymph nodes
+∞
6.3
6
*
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
+∞
6.3
6
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
C46.7
ICD-10 Finland
Kaposi sarcoma of other sites
+∞
6.3
6
*
130
Kela drug reimbursment
Malignant tumour
+∞
6.3
6
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
6.3
6
*
J01MA12
ATC
levofloxacin; systemic
4.2
6.0
21
68
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
62
3.13
3.36
13.2
5.5
0.92
1.09
mmol/l
1.42
16
57
17
71
2.92
3.14
2.2
2.7
1.94
0.72
e6/l
—
8
34
24
121
2.60
3.11
3.1
3.0
0.01
0.35
e6/l
2.13
18
85
5
5
10.71
3.03
5.4
1.2
—
—
—
0
0
17
74
2.79
2.90
2.8
2.9
2.06
1.53
e6/l
—
8
37
7
14
5.48
2.81
1.6
1.4
—
—
—
0
0
5
6
8.92
2.80
5.4
1.2
—
—
—
0
0
5
6
8.92
2.80
2.4
1.0
—
—
—
0
0
8
19
4.67
2.78
4.2
1.6
—
—
—
0
0
10
30
3.77
2.75
2.2
1.3
—
—
—
0
0
35
222
2.32
2.66
16.0
3.1
10.53
13.81
umol/l
1.33
35
211
5
7
7.64
2.59
1.2
2.0
—
—
—
0
0
5
7
7.64
2.59
2.4
1.1
—
—
—
0
0
11
42
2.96
2.29
4.6
3.3
—
—
—
0
0
33
214
2.16
2.27
5.3
3.6
0.00
0.00
estimate
—
7
49
33
215
2.14
2.23
8.6
6.1
1.19
1.21
mmol/l
0.54
28
184
27
164
2.14
2.17
6.6
2.3
—
—
estimate
—
0
0
33
220
2.07
2.06
5.6
3.7
0.00
0.00
estimate
—
9
47
13
60
2.48
1.94
3.5
2.7
24.92
21.19
%
0.23
13
55
15
75
2.32
1.89
2.1
1.7
—
—
—
0
0
6
17
3.79
1.88
5.0
1.4
—
—
—
0
0
32
216
2.00
1.88
5.7
3.6
0.00
0.00
estimate
—
9
50
19
106
2.14
1.85
4.5
2.7
361.21
389.02
umol/l
0.65
19
89
8
31
2.81
1.73
2.9
4.8
62.37
90.87
ng/l
—
8
23
14
71
2.26
1.70
3.9
2.5
10.13
11.94
umol/l
0.41
14
66
13
65
2.27
1.63
3.8
2.5
2.13
2.19
g/l
0.09
13
58
6
21
3.05
1.54
2.5
1.5
—
—
—
0
0
6
21
3.05
1.54
5.7
1.6
0.51
1.29
ug/l
—
6
16
15
83
2.06
1.47
3.2
2.0
—
—
—
0
0
29
205
1.78
1.37
1.9
2.2
84.02
88.47
pmol/l
0.23
18
99
5
18
2.93
1.31
2.2
1.3
—
—
—
0
0
5
19
2.77
1.24
1.6
1.4
—
—
—
0
0
10
51
2.15
1.19
1.7
1.7
—
—
—
0
0
10
55
1.98
0.99
1.5
1.7
—
—
—
0
0
18
122
1.67
0.94
4.5
3.5
0.00
0.00
estimate
—
7
40
8
44
1.94
0.90
2.8
7.2
111.50
122.84
g/l
—
8
44
27
211
1.50
0.76
2.3
2.4
—
—
—
0
0
19
138
1.54
0.74
2.4
1.8
50.58
90.47
u/l
0.61
19
129
5
29
1.79
0.65
1.0
1.4
—
—
—
0
0
6
35
1.79
0.60
5.3
4.7
1.22
2.85
mmol/l
—
6
24
17
131
1.41
0.49
6.6
3.2
0.00
0.00
estimate
—
6
35
46
426
1.31
0.34
37.6
20.3
138.89
139.83
mmol/l
1.51
46
415
20
167
1.29
0.34
5.9
3.5
0.00
0.00
estimate
—
7
36
46
428
1.29
0.31
37.6
20.2
4.00
4.03
mmol/l
0.26
46
417
8
64
1.29
0.29
4.5
5.4
103.00
104.73
mmol/l
—
8
64
48
451
1.28
0.28
52.1
22.6
131.27
136.26
g/l
1.11
48
441
47
443
1.25
0.25
44.2
21.0
83.94
88.94
umol/l
0.62
47
431
5
39
1.31
0.23
3.0
1.4
1.36
1.72
%
—
5
33
5
39
1.31
0.23
1.2
1.6
—
—
—
0
0
19
165
1.22
0.23
2.1
2.2
142.47
646.52
u/l
0.61
19
156
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
47
451
1.17
0.15
53.0
22.7
39.60
40.47
%
0.55
47
441
47
451
1.17
0.15
52.8
22.4
92.46
91.29
fl
0.91
47
441
19
180
1.08
0.04
6.3
3.7
18.00
24.99
%
—
6
77
41
401
1.07
0.03
14.1
5.6
6.07
6.20
mmol/l
0.37
36
358
14
136
1.04
0.00
3.6
2.8
0.69
0.78
ug/l
—
9
83
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_KAPOSI_SARCOMA_WIDE – Kaposi sarcoma, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).